Events

Feb
23
2021

9th Neurodegenerative Drug Development Summit 2021

Clinical

Event Summary

This virtual meeting will aim to satisfy the industry's need to share cutting edge research, learn from peers and engage in quality networking from the comfort and safety of your home or office

Event Description

Whether you are working in a team dedicated to Parkinson’s, Alzheimer’s, Lewy Body Dementia or a rare neurodegenerative disorder, this intimate, industry-led forum is not only an opportunity to learn from those pioneering this space, but to network and build meaningful partnerships with over 150 neurodegenerative drug development experts. After all, collaboration in this industry is pivotal!

Across 3 action-packed, case-study driven days, and 2 parallel tracks of learning, we present the opportunity to join us online in 2021 to overcome the challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit.

The digital agenda will address the following hot topics and translational challenges:

Discover diverse approaches to regeneration therapeutics with Aspen Neuroscience and Neuronascent, and explore cellular approaches to neurodegenerative drug discovery with Noveome

Hear novel approaches to developing protein misfolding-specific therapies for the treatment of neurodegeneration with ProMis Neurosciences and Origami Therapeutics

Evaluate pioneering approaches to clinical design for ALS with Harvard Medical School and hear how Roche are targeting Alpha-Synuclein to design the next-generation of clinical trials

Investigate post-translational modifications as a new therapeutic approach for CNS disorders with Circumvent Pharmaceuticals and hear how Stoke Therapeutics are developing a unique therapeutic approach to tackle neurodegenerative disorders using antisense oligonucleotides

Explore the implementation of novel blood-based biomarkers, evaluate the role of CNS exosomes in diagnosing AD & PD and assess an encyclopedia of available biomarkers for neurodegenerative diseases with Zetterberg, the EMA, Eli Lilly & Company, Rissman and Teunissen

Unpack the role that genetics play in neurodegenerative diseases and explore emerging new gene therapies for CNS indications with Eisai and Brain Neurotherapy Bio

With its most discussion-led format yet, the Neurodegenerative Drug Development provides unrivalled networking opportunities for you to catch up with friendly faces and make new connections to establish future partnerships.

Price

Drug Developer - Conference Only - USD 1799.0
Drug Developer - Conference + 1 Workshop - USD 2098.0
Drug Developer - Conference + 2 Workshops - USD 2397.0
Drug Developer - Conference + 3 Workshops - USD 2696.0
Drug Developer - Conference + 4 Workshops - USD 2995.0
Solution Provider - Conference Only - USD 2339.0
Solution Provider - Conference + 1 Workshop - USD 2698.0
Solution Provider - Conference + 4 Workshops - USD 3595.0
Academic/Start Up - Conference Only - USD 1099.0
Academic/Start Up - Conference + 4 Workshops - USD 1895.0

Links

BUY TICKETS NOW
BUY TICKETS NOW
BUY TICKETS NOW

This virtual meeting will aim to satisfy the industry's need to share cutting edge research, learn from peers and engage in quality networking from the comfort and safety of your home or office
Venue

United States
United States
US
67340

Contact

Sophie Ellis
info@hansonwade.com
+1 617 455 4188

Starts:
23-02-2021
15:00

Ends:
25-02-2021
23:00